Carrie Bourdow
Chief Executive Officer chez TREVENA, INC.
Fortune : 43 442 $ au 31/03/2024
Postes actifs de Carrie Bourdow
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01/10/2018 | - |
| Chairman | 01/01/2024 | - | |
| President | 01/10/2018 | - | |
| Director/Board Member | 01/10/2018 | 01/01/2024 | |
| Chief Operating Officer | 02/02/2018 | 01/10/2018 | |
| Corporate Officer/Principal | 04/05/2015 | 02/02/2018 |
Historique de carrière de Carrie Bourdow
Anciens postes connus de Carrie Bourdow
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 23/06/2017 | 30/07/2023 |
| Independent Dir/Board Member | 23/06/2017 | 30/07/2023 | |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 20/02/2020 | 07/03/2023 |
| Independent Dir/Board Member | 20/02/2020 | 07/03/2023 | |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/05/2013 | 01/05/2015 |
Formation de Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 6 |
| Irlande | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Carrie Bourdow
- Expérience
